Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis

Cited by (497)

Items 201–300 of 497

1. Sodium–glucose cotransporter-2 inhibitor alleviated atrial remodeling in STZ-induced diabetic rats by targeting TLR4 pathway
   Xiaoping Zhan, Lijun Cheng, Ning Huo, Lin Yu, Changle Liu, Tong Liu, Guangping Li, Huaying Fu · 2022 · Frontiers in Cardiovascular Medicine
2. Growing role of SGLT2i in heart failure: evidence from clinical trials
   Ajay K. Varadhan, Katarina Stephan, Rahul Gupta, Apurva Vijay Vyas, Purva Ranchal, Wilbert S. Aronow, Nael Hawwa, Gregg M. Lanier · 2022 · Expert Review of Clinical Pharmacology
3. Body fluid regulation via chronic inhibition of sodium–glucose cotransporter-2 in patients with heart failure: a post hoc analysis of the CANDLE trial
   Shinya Fujiki, Atsushi Tanaka, Takumi Imai, Michio Shimabukuro, Hiroki Uehara, Ikuko Nakamura, Kazuo Matsunaga, Makoto Suzuki, Takeshi Kashimura, Tohru Minamino et al. · 2022 · Clinical Research in Cardiology
4. Effect of Dapagliflozin on Indicators of Myocardial Fibrosis and Levels of Inflammatory Factors in Heart Failure Patients
   Chuanqiang Wang, Yiteng Qin, Xiaojun Zhang, Yang Yang, Xuan Wu, Jing Liu, Shuhui Qin, Ke Chen, Wenliang Xiao · 2022 · Disease Markers
5. Diabetes, Heart Failure and Beyond: Elucidating the Cardioprotective Mechanisms of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors
   Utkarsh Ojha, Lenisse M. Reyes, Florence Eyenga, Diane Oumbe, Justyna Watkowska, Henock Saint-Jacques · 2021 · American Journal of Cardiovascular Drugs
6. Contemporary Perspectives on Congestion in Heart Failure: Bridging Classic Signs with Evolving Diagnostic and Therapeutic Strategies
   Mihai Grigore, Camelia Nicolae, Andreea-Maria Grigore, Ana-Maria Balahura, Nicolae Păun, Gabriela Uscoiu, Ioana Verde, Adriana-Mihaela Ilieșiu · 2025 · Diagnostics
7. Sodium-Glucose Cotransporter-2 Inhibitor Use is Associated with a Reduced Risk of Heart Failure Hospitalization in Patients with Heart Failure with Preserved Ejection Fraction and Type 2 Diabetes Mellitus: A Real-World Study on a Diverse Urban Population
   Weijia Li, Adarsh Katamreddy, Rachna Kataria, Merle L. Myerson, Cynthia C. Taub · 2021 · Drugs - Real World Outcomes
8. Suppression of Cardiogenic Edema with Sodium–Glucose Cotransporter-2 Inhibitors in Heart Failure with Reduced Ejection Fraction: Mechanisms and Insights from Pre-Clinical Studies
   Ryan D. Sullivan, Mariana E. McCune, Michelle Hernandez, Guy L. Reed, Inna P. Gladysheva · 2022 · Biomedicines
9. Rediscovery of the Implication of Albuminuria in Heart Failure: Emerging Classic Index for Cardiorenal Interaction
   Kyung-Duk Min, Yuki Matsumoto, Masanori Asakura, Masaharu Ishihara · 2024 · ESC Heart Failure
10. Effects of Sodium–Glucose Co-transporter 2 Inhibition with Empaglifozin on Renal Structure and Function in Non-diabetic Rats with Left Ventricular Dysfunction After Myocardial Infarction
    Salva R. Yurista, Herman H.W. Silljé, Harry van Goor, Jan‐Luuk Hillebrands, Hiddo J.L. Heerspink, Luiz de Menezes Montenegro, Silke U. Oberdorf‐Maass, Rudolf A. de Boer, Berend Daan Westenbrink · 2020 · Cardiovascular Drugs and Therapy
11. Hybrid modelling for stroke care: Review and suggestions of new approaches for risk assessment and simulation of scenarios
    Tilda Herrgårdh, Vince I. Madai, John D. Kelleher, Rasmus Magnusson, Mika Gustafsson, Lili A. Milani, Peter Gennemark, Gunnar Cedersund · 2021 · NeuroImage Clinical
12. Impact of Sodium–Glucose Co-Transporter 2 Inhibitors on Cardiac Protection
    Victor Chien‐Chia Wu, Yanrong Li, Chao‐Yung Wang · 2021 · International Journal of Molecular Sciences
13. Effects of 1‐year treatment with canagliflozin on body composition and total body water in patients with type 2 diabetes
    Ikuro Matsuba, Masahiro Takihata, Masahiko Takai, Hajime Maeda, Akira Kubota, Kotaro Iemitsu, Shinichi Umezawa, Mitsuo Obana, Mizuki Kaneshiro, Takehiro Kawata et al. · 2021 · Diabetes Obesity and Metabolism
14. Emerging concepts in heart failure treatment and management: focus on SGLT2 inhibitors in heart failure with preserved ejection fraction
    Andrea Beatriz De Lorenzi, Edgardo Kaplinsky, Marx Rivera Zambrano, Laia Tomas Chaume, Joan Monell Rosas · 2023 · Drugs in Context
15. Clinical pharmacology of SGLT-2 inhibitors in heart failure
    Maria Velliou, Effie Polyzogopoulou, Ioannis Ventoulis, John Parissis · 2023 · Expert Review of Clinical Pharmacology
16. Predicted Cardiac Hemodynamic Consequences of the Renal Actions of SGLT2i in the DAPA‐HF Study Population: A Mathematical Modeling Analysis
    Hongtao Yu, Weifeng Tang, Peter J. Greasley, Robert C. Penland, David W. Boulton, K. Melissa Hallow · 2020 · The Journal of Clinical Pharmacology
17. Surprises in cardiology: efficacy of gliflozines in heart failure even in the absence of diabetes
    Alessio Bragagni, Federica Piani, Claudio Borghi · 2021 · European Heart Journal Supplements
18. Myocardial Ketone Body Oxidation Contributes to Empagliflozin-Induced Improvements in Cardiac Contractility in Murine Heart Failure
    Suzanne N. Voorrips, Constantin Laurent Palm, Huitzilihuitl Saucedo‐Orozco, Belend Mahmoud, Elisabeth M. Schouten, Anna M. Feringa, Pablo Sánchez-Aguilera, Kirsten T. Nijholt, Salva R. Yurista, Peter van der Meer et al. · 2025 · European Journal of Heart Failure
19. Impact of SGLT2 Inhibitors on Cardiovascular Risk Scores, Metabolic Parameters, and Laboratory Profiles in Type 2 Diabetes
    Nazif Yalçın, Selman Aktaş, Seyit Uyar, Nizameddin Koca · 2025 · Life
20. A holistic view of SGLT2 inhibitors: From cardio-renal management to cognitive and andrological aspects
    Rossella Cannarella, Michele Rubulotta, Vittorio Cannarella, Sandro La Vignera, Aldo Eugenio Calogero · 2025 · European Journal of Internal Medicine
21. Potential favorable action of sodium-glucose cotransporter-2 inhibitors on sudden cardiac death: a brief overview
    Tatsuya Sato, Hidemichi Kouzu, Toshiyuki Yano, Ichiro Sakuma, Masato Furuhashi, Noritsugu Tohse · 2023 · Frontiers in Cardiovascular Medicine
22. Prevention of Heart Failure With SGLT-2 Inhibition
    Michael E. Farkouh, Subodh Verma · 2018 · Journal of the American College of Cardiology
23. Renal Effects of Dapagliflozin in People with and without Diabetes with Moderate or Severe Renal Dysfunction: Prospective Modeling of an Ongoing Clinical Trial
    K. Melissa Hallow, David W. Boulton, Robert C. Penland, Gabriel Helmlinger, Emily Nieves, Daniël H. van Raalte, Hiddo J.L. Heerspink, Peter J. Greasley · 2020 · Journal of Pharmacology and Experimental Therapeutics
24. Sacubitril/valsartan, sodium‐glucose cotransporter 2 inhibitors and vericiguat for congestive heart failure therapy
    Tobias Norre, Daniela G. Grimm, Ulf Simonsen · 2022 · Basic & Clinical Pharmacology & Toxicology
25. Exploring the Protective Effects of Taxifolin in Cardiovascular Health: A Comprehensive Review
    Hwan-Hee Sim, Ju-Young Ko, Dal-Seong Gong, Dong‐Wook Kim, Jung Jin Kim, Han-Kyu Lim, Hyun Jung Kim, Min–Ho Oak · 2025 · International Journal of Molecular Sciences
26. Proposal for New Classification and Practical Use of Diuretics According to Their Effects on the Serum Chloride Concentration: Rationale Based on the “Chloride Theory”
    Hajime Kataoka · 2020 · Cardiology and Therapy
27. SGLT-2 Inhibitors: The Next-generation Treatment for Type 2 Diabetes Mellitus
    Nikola Lukic, Mirjana Mačvanin, Zoran M. Gluvic, Manfredi Rizzo, Djordje J. Radak, Jasjit S. Suri, Esma R. Isenović · 2023 · Current Medicinal Chemistry
28. Management of Hypertension in Diabetic Kidney Disease
    Gates B. Colbert, Mohamed Essam Elrggal, Anna R. Gaddy, Hector M. Madariaga, Edgar V. Lerma · 2023 · Journal of Clinical Medicine
29. SGLT-2 inhibitors: A step forward in the treatment of heart failure with reduced ejection fraction
    José Silva‐Cardoso, Aurora Andrade, Dulce A. Brito, Jorge Ferreira, Cândida Fonseca, Marisa Peres, Fátima Franco, Brenda Moura · 2021 · Revista Portuguesa de Cardiologia
30. Quantification and treatment of congestion in heart failure: A clinical and pathophysiological overview
    Rafael de la Espriella, Enrique Santas, Isabel Zegrí Reiriz, José Luis Górriz, Marta Cobo Marcos, Julio E. Núñez · 2022 · Nefrología (English Edition)
31. Prognostic Significance of Plasma Chloride in Elderly Patients Hospitalized for Acute Heart Failure
    Pau Llàcer, François Croset, Julio E. Núñez, Jorge Campos, Cristina Fernández, M. Fabregate, Beatriz Del Hoyo Cuenda, Raúl Ruiz, Genoveva López, Susana Tello et al. · 2023 · ESC Heart Failure
32. Impact of glucagon like peptide-1 receptor agonist and sodium glucose cotransporter 2 inhibitors on type 2 diabetes patients with renal impairment
    Takeyuki Hiramatsu, Hiroki Ito, Shota Okumura, Yuko Asano, Daiki Iguchi, Shinji Furuta · 2020 · Diabetes and Vascular Disease Research
33. Renal Oxygen Demand and Nephron Function: Is Glucose a Friend or Foe?
    Edoardo Gronda, Massimo Iacoviello, Alberto Palazzuoli, Manuela Benevenuto, Domenico Gabrielli, Arduino Arduini · 2023 · International Journal of Molecular Sciences
34. Hypovolemia and reduced hemoglobin mass in patients with heart failure and preserved ejection fraction
    David Montero, Thomas Haider, Jens Barthelmes, Jens Peter Goetze, Silviya Cantatore, Isabella Sudano, Frank Thomas Ruschitzka, Andreas J. Flammer · 2019 · Physiological Reports
35. What Makes Sodium-Glucose Co-Transporter-2 Inhibitors Stand out in Heart Failure?
    Muhammad Shahzeb Khan, Muthiah Vaduganathan · 2020 · Current Diabetes Reports
36. Impact of SGLT2 inhibitors on cardiovascular outcomes in patients with heart failure with reduced ejection fraction
    Jessica A. Starr, Nathan A. Pinner, Katelin M. Lisenby, Alyssa J. Osmonson · 2021 · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
37. Inhibitors of sodium-glucose transport protein 2: A new multidirectional therapeutic option for heart failure patients
    Jacek Kubica, Aldona Kubica, Klaudyna Grzelakowska, Wioleta Stolarek, Zofia Grąbczewska, Piotr Michalski, Piotr Niezgoda, Stanisław Bartuś, Andrzej Budaj, Mariusz Dąbrowski et al. · 2021 · Cardiology Journal
38. Comparison of the effects of empagliflozin and glimepiride on endothelial function in patients with type 2 diabetes: A randomized controlled study
    Haruka Tamura, Yoshinobu Kondo, Kohei Ito, Masanori Hasebe, Shinobu Satoh, Yasuo Terauchi · 2022 · PLoS ONE
39. Mechanisms underlying the blood pressure‐lowering effects of empagliflozin, losartan and their combination in people with type 2 diabetes: A secondary analysis of a randomized crossover trial
    Rosalie Annemien Scholtes, Charlotte M. Mosterd, Anne C. Hesp, Mark M. Smits, Hiddo J.L. Heerspink, Daniël H. van Raalte · 2022 · Diabetes Obesity and Metabolism
40. SGLT-2 Inhibitors in Heart Failure: Guide for Prescribing and Future Perspectives
    Vishnu Vardhan Garla, Javed Butler, Lillian F. Lien · 2021 · Current Cardiology Reports
41. Dapagliflozin-Induced Myocardial Flow Reserve Improvement is not Associated with HDL Ability to Stimulate Endothelial Nitric Oxide Production
    Umberto Capece, Chiara Pavanello, Francesca Cinti, Lucia Leccisotti, Teresa Mezza, Gea Ciccarelli, Simona Moffa, Gianfranco Di Giuseppe, Laura Soldovieri, Michela Brunetti et al. · 2023 · Diabetes Therapy
42. Prediction of the effect of dapagliflozin on kidney and heart failure outcomes based on short-term changes in multiple risk markers
    Nienke M. A. Idzerda, Bergur V. Stefánsson, Michelle J. Pena, C. David Sjöström, David Collins. Wheeler, Hiddo J.L. Heerspink · 2019 · Nephrology Dialysis Transplantation
43. Advantages of therapy with sodium glucose cotransporter type 2 inhibitors in patients with type 2 diabetes mellitus in combination with hyperuricemia and gout
    Тарас Сергеевич Паневин, М. С. Елисеев, Marina Vladimirovna Shestakova, Evgeny Lvovich Nasonov · 2020 · Terapevticheskii arkhiv
44. Cardioprotective Effects of Dapagliflozin and Trimetazidine on Doxorubicin-Induced Cardiotoxicity in Streptozotocin-Induced Type 1 Diabetic Rats via Endoplasmic Reticulum Stress
    Muhammed Mürsel Öğütveren, Ömer Şatıroğlu, Zülkar Özden, Kerimali Akyıldız, Adnan Yılmaz, Filiz Mercantepe, Ahmet Seyda Yilmaz, Haldun Koç, Tolga Mercantepe · 2025 · Journal of Clinical Medicine
45. Cardiac digital twins: a tool to investigate the function and treatment of the diabetic heart
    Marina Strocchi, Daniel J. Hammersley, Brian P. Halliday, Sanjay Kumar Prasad, Steven Niederer · 2025 · Cardiovascular Diabetology
46. Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure
    Kevin Shah, James C. Fang · 2021 · The Annual Review of Pharmacology and Toxicology
47. Electrocardiographic changes associated with SGLT2 inhibitors and non-SGLT2 inhibitors: A multi-center retrospective study
    Victor Chien‐Chia Wu, Kai-Pin Chiu, Chunli Wang, Chiu-Yi Hsu, Hui‐Tzu Tu, Yu‐Tung Huang, Chih‐Hsiang Chang, Chien‐Hao Huang, Chang‐Fu Kuo, Shao‐Wei Chen et al. · 2022 · Frontiers in Cardiovascular Medicine
48. The effects of empagliflozin on measured glomerular filtration rate and estimated extracellular and plasma volumes in patients with type 2 diabetes
    Mikkel Jürgens, Morten Schou, Philip Hasbak, Andreas Kjær, Emil Wolsk, Bo Zerahn, Niels Brandt, Peter Gæde, Peter R Rossing, Jens Oscar Faber et al. · 2023 · Diabetes Obesity and Metabolism
49. Novel Antidiabetic Agents: Cardiovascular and Safety Outcomes
    Gerasimos Siasos, Evanthia Bletsa, Panagiota K. Stampouloglou, Stavroula Α. Paschou, Evangelos K. Oikonomou, Vasiliki Tsigkou, Alexios S. Antonopoulos, Manolis Vavuranakis, Dimitrios M. Tousoulis · 2020 · Current Pharmaceutical Design
50. SGLT2 Inhibitors: A Broad Impact Therapeutic Option for the Nephrologist
    Antonio Raffaele Michele Granata, Francesco Pesce, Massimo Iacoviello, Massimiliano Anzaldi, Francesco Amico, Maria Rosaria Catalano, Giuseppe Leonardi, Carmela Gatta, Giusy Costanza, Salvatore Corrao et al. · 2022 · Frontiers in Nephrology
51. Biomolecular Mechanisms of Cardiorenal Protection with Sodium-Glucose Co-Transporter 2 Inhibitors
    Francesca Romana Prandi, Lucy Barone, Dalgisio Lecis, Martina Belli, Domenico Sergi, Marialucia Milite, Stamatios Lerakis, Francesco Romeo, Francesco Barillà · 2022 · Biomolecules
52. Anti-Diabetic Therapy and Heart Failure: Recent Advances in Clinical Evidence and Molecular Mechanism
    Chih‐Neng Hsu, Chin‐Feng Hsuan, Daniel Liao, Jack. Keng-Jui Chang, Allen Jiun-Wei Chang, Siow‐Wey Hee, Hsiao-Lin Lee, Sean I. F. Teng · 2023 · Life
53. Effect of Dapagliflozin on Patients with Rheumatic Heart Disease Mitral Stenosis
    An Aldia Asrial, Reviono Reviono, Soetrisno Soetrisno, Budi Yuli Setianto, Vitri Widyaningsih, Ida Nurwati, Brian Wasita, Anggit Pudjiastuti · 2023 · Journal of Clinical Medicine
54. Impact of sodium-glucose cotransporter-2 inhibitors on pulmonary vascular cell function and arterial remodeling
    Jingjing Zhang, Xue-Rui Ye, Xuesong Liu, Hao-Ling Zhang, Qian Qiao · 2025 · World Journal of Cardiology
55. Complementary Yet Distinct Roles of GLP-1 Receptor Agonists and SGLT2 Inhibitors in Cardiovascular Risk Reduction
    Nóra Homoródi, Éva Varga, Zoltán Szabó, Ferenc Sztanek, Mariann Harangi · 2025 · Biomedicines
56. Chronic cardiorenal syndrome: cardio-renal protective effect of SGLT2i
    Yixin Zhu, Chenxi Lv, Hanqi Yang, Qian Lü, XuChen Wang, Yueqi Zhang, Maojuan Guo, Bo Yang · 2025 · Renal Failure
57. Obesity-related heart failure with preserved ejection fraction: new treatment strategies
    Steven G. Chrysant, George S. Chrysant · 2019 · Hospital Practice
58. A Meta-Analysis of the Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Heart Failure and Preserved Ejection Fraction
    Ahmad Al‐Abdouh, Mohammed Mhanna, Mahmoud Barbarawi, Waiel A. Abusnina, Vedant Arun Gupta · 2021 · The American Journal of Cardiology
59. The Safety and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors for Patients with Sarcopenia or Frailty: Double Edged Sword?
    Ayami Naito, Yuji Nagatomo, Akane Kawai, Midori Iwashita, Ryota Nakazawa, Akira Taruoka, Asako Takefuji, Risako Yasuda, Takumi Toya, Yukinori Ikegami et al. · 2024 · Journal of Personalized Medicine
60. An Overview of Prospective Drugs for Type 1 and Type 2 Diabetes
    Ping Wu, Zhenyu Liu, Xiaohong Jiang, Hao Fang · 2019 · Current Drug Targets
61. Does SGLT2 Inhibition Affect Sympathetic Nerve Activity in Type 2 Diabetes?
    Rumyana B. Dimova, Tsvetalina I. Tankova · 2020 · Hormone and Metabolic Research
62. Possible Mechanisms of Action of SGLT2 Inhibitors in Heart Failure
    Camila Nicolela Geraldo Martins, Adriana Aparecida Bau, Luis Miguel da Silva, Otávio R. Coelho‐Filho · 2021 · ABC Heart Failure & Cardiomyopathy
63. SGLT2 inhibitors: a new pillar of the heart failure regimen
    Travis B. DeSa, Timothy Gong · 2021 · Reviews in Cardiovascular Medicine
64. Interaction between sodium-glucose co-transporter 2 and the sympathetic nervous system
    Omar Azzam, Vance B. Matthews, Markus Peter Schlaich · 2021 · Current Opinion in Nephrology & Hypertension
65. Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Mahmoud Ismayl, Muhannad Aboud Abbasi, Abdullah K. Al-Abcha, Edward A El-Am, Scott W. Lundgren, Andrew Michael Goldsweig, Nandan Sadanand Anavekar · 2023 · Current Problems in Cardiology
66. Sodium-Glucose Cotransporter 2 Inhibitors: A Scoping Review of the Positive Implications on Cardiovascular and Renal Health and Dynamics for Clinical Practice
    Saliha Erdem, Anoop Titus, Dhruvil Patel, Neel N Patel, Yasar Sattar, James Glazier, Chadi M. Alraies · 2023 · Cureus
67. Efficacy and safety of sodium-glucose cotransporter 2 (SGLT2) inhibitors in patients with acute heart failure: a systematic review and meta-analysis
    Jingjin Hou, Li Ren, Qingbin Hou, Xiaodong Jia, Zhu Mei, Jiaxin Xu, Zheming Yang, Yiming Li, Chenghui Yan · 2024 · Frontiers in Cardiovascular Medicine
68. Effects of dapagliflozin on sodium excretion, blood pressure and volume status in patients with type 2 diabetes and/or chronic kidney disease: The DAPASALT trial
    Jelle M. Beernink, Niels Jongs, Charlotte M. Mosterd, Rosalie Annemien Scholtes, Alyssa Caldwell‐McGee, Daniel Isaiah Casillas, Lynette M. Driscoll, Peter J. Greasley, Cecilia Karlsson, Ann Hammarstedt et al. · 2025 · Diabetes Obesity and Metabolism
69. Nephroprotective Mechanisms of SGLT2i: Beyond the Glucose-Lowering Effect
    Alessio Mazzieri, Livia M. R. Marcon · 2025 · Biomedicines
70. Sodium-Glucose Cotransporter 2 Inhibitors in Autosomal Dominant Polycystic Kidney Disease
    Marie Therese Bou Antoun, Abdul Hamid Borghol, Levon Souvalian, Mohamad Hadla, Georges Abboud, Ahmad Ghanem, Fadi George Munairdjy Debeh, Jean Marc Mardirossian, Mahdi Salih, Pranav Sandilya Garimella et al. · 2025 · Journal of the American Society of Nephrology
71. Sotagliflozin vs Dapagliflozin: A Systematic Review Comparing Cardiovascular Mortality
    Nandhini Iyer, Sally Hussein, Sanjana Singareddy, Vijay Prabhu SN, Arturo P Jaramillo, Mohamed B. Yasir, Tuheen Sankar Nath · 2023 · Cureus
72. Second revolution in cardiovascular prevention
    Chern‐En Chiang, Kang-Ling Wang, Hao‐Min Cheng, Shih‐Hsien Sung, Tze‐Fan Chao · 2020 · Journal of the Chinese Medical Association
73. Association of estimated plasma volume and weight loss after long‐term administration and subsequent discontinuation of the sodium‐glucose cotransporter‐2 inhibitor tofogliflozin
    Yasuhiro Matsubayashi, Akihiro Yoshida, Hideki Suganami, Momoko Oe, Takaaki Sato, Yuta Yaguchi, Kazuya Fujihara, Takaho Yamada, Shiro Tanaka, Kohei Kaku et al. · 2021 · Diabetes Obesity and Metabolism
74. Sodium-Glucose Cotransporter-2 Inhibitors-from the Treatment of Diabetes to Therapy of Chronic Heart Failure
    Dominik Kurczyński, Bartosz Hudzik, Marta Jagosz, Jan Zabierowski, Jolanta Urszula Nowak, Andrzej Robert Tomasik, Arkadiusz Bądziński, Piotr Rozentryt, Mariusz Gąsior · 2022 · Journal of Cardiovascular Development and Disease
75. How to position sodium-glucose co-transporter 2 inhibitors in the management of diabetes in acromegaly patients
    Adnan Zaina, Nunzia Prencipe, Elena Golden, Alessandro Maria Berton, Eldad Arad, Abid Ali, Jeryes Shehadeh, Sameer Kassem, Ezio Ghigo · 2023 · Endocrine
76. Long-term observation of estimated fluid volume reduction after the initiation of ipragliflozin in patients with type 2 diabetes mellitus: a sub-analysis from a randomized controlled trial (PROTECT)
    Atsushi Tanaka, Takumi Imai, Shigeru Toyoda, Kazuhiro Sugimoto, Ruka Yoshida, Machi Furuta, Koichi Node, the PROTECT Investigators · 2023 · Diabetology & Metabolic Syndrome
77. Rationale and Design of the CANONICAL Study ― Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Canagliflozin for Heart Failure With Preserved Ejection Fraction With Type 2 Diabetes Mellitus ―
    Shu Kasama, Tohru Masuyama, Shiro Uemura, Yukihito Sato, Shinya Hiramitsu, Izuru Masuda, Kazuhiro Yamamoto, Sei Komatsu, Toshihisa Anzai, Kunihiro Nishimura et al. · 2019 · Circulation Reports
78. Current and future approaches to nonclinical cardiovascular safety assessment
    Teresa A. Collins, Michael G. Rolf, Amy Pointon · 2020 · Drug Discovery Today
79. An evaluation of canagliflozin for the treatment of type 2 diabetes: an update
    Taichi Minami, Akiko Kameda, Yasuo Terauchi · 2021 · Expert Opinion on Pharmacotherapy
80. Diving into the Unknown: Sodium–Glucose Cotransporter-2 Inhibitors in Heart Failure without Diabetes
    Petar M Seferovic, Jelena P. Seferović, Marija M. Polovina · 2019 · European Journal of Heart Failure
81. Sodium–Glucose Co-Transporter 2 Inhibitors and Acute Heart Failure
    Amy Groenewegen, Frans Hendrik Rutten · 2020 · European Journal of Heart Failure
82. Hypoxia, ROS, and HIF Signaling in I/R Injury: Implications and Future Prospects
    Manish Kumar Singh, Hyeong Rok Yun, Jyotsna Suresh Ranbhise, Sunhee Han, Sung Soo Kim, Insug Kang · 2026 · Antioxidants
83. Beneficial cardiovascular and remodeling effects of SGLT 2 inhibitors
    Steven G. Chrysant, George S. Chrysant · 2022 · Expert Review of Cardiovascular Therapy
84. Renal disease in patients with type 2 diabetes: Magnitude of the problem, risk factors and preventive strategies
    Luigi Gnudi · 2022 · La Presse Médicale
85. Evaluation of Inpatient Sodium-Glucose Co-Transporter-2 Inhibitor Use in Patients Hospitalized for Acute Heart Failure
    Crystal Lihong Yan, Austin Erben, Rhea B. Sancassani · 2023 · The American Journal of Cardiology
86. Protective effect of canagliflozin on post-resuscitation myocardial function in a rat model of cardiac arrest
    Tianfeng Hua, Yuqian Chu, Minjie Wang, Yijun Zhang, Wei Shi, Qihui Huang, Liangliang Zhang, Min Yang · 2023 · Intensive Care Medicine Experimental
87. The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure, Regardless of Diabetes Status: Focus on Cardiovascular Disease
    Filipe Ferrari, Vítor Magnus Martins, Rafael Selbach Scheffel, Anderson Donelli da Silveira, Marcelo Trotte Motta, Emílio Hideyuki Moriguchi, Raul Dias Santos, Ricardo Stein · 2021 · Annals of Pharmacotherapy
88. Pharmacologic and interventional paradigms of diuretic resistance in congestive heart failure: a narrative review
    Simge Acar, Sueda Sanli, Cinar Oztosun, Barış Afşar, Alan Alper Sag, Masanari Kuwabara, Adrian Constantin Covic, Alberto Ortíz, Mehmet Kanbay · 2021 · International Urology and Nephrology
89. Reno-protective potential of sodium glucose cotransporter-2 (SGLT2) inhibitors: Summary evidence from clinical and real-world data
    Niti Mittal, Vikas Sehray, Rakesh Mittal, Surjit Singh · 2021 · European Journal of Pharmacology
90. Predicted Cardiac Functional Responses to Renal Actions of SGLT2i in the DAPACARD Trial Population: A Mathematical Modeling Analysis
    Hongtao Yu, Sanchita Basu, Weifeng Tang, Robert C. Penland, Peter J. Greasley, Jan Oscarsson, David W. Boulton, K. Melissa Hallow · 2021 · The Journal of Clinical Pharmacology
91. Cardiovascular benefits beyond urinary glucose excretion: A hypothesis generated from two meta‐analyses
    Chu Lin, Xiaoling Cai, Linong Ji · 2021 · Diabetes Obesity and Metabolism
92. Novel Medical Treatments and Devices for the Management of Heart Failure with Reduced Ejection Fraction
    Michele Alfieri, Filippo Bruscoli, Luca Di Vito, Federico Di Giusto, Giancarla Scalone, Procolo Marchese, Domenico Delfino, Simona Silenzi, Milena Martoni, Federico Guerra et al. · 2024 · Journal of Cardiovascular Development and Disease
93. Important Considerations for the Treatment of Patients with Diabetes Mellitus and Heart Failure from a Diabetologist’s Perspective: Lessons Learned from Cardiovascular Outcome Trials
    Chrysi C. Koliaki, Nicholas L. Katsilambros · 2019 · International Journal of Environmental Research and Public Health
94. Efficacy and safety of SGLT2 inhibitors in acute heart failure: a systematic review and meta-analysis of randomized controlled trials
    Ali Rahil, Tirth Bhavsar, Rida Fatima, Aparajitha Rajkumar, Joy Kumar, Hanif Al Majidan, Namrata Gajjala, WODWENTZKY LEFRANC, Fnu Deeksha, Harshitha Lingegowda et al. · 2025 · Frontiers in Cardiovascular Medicine
95. Sodium-glucose transporter 2 inhibitors and cardiovascular-kidney-metabolic syndrome: a narrative review
    Yuqing Wang, Yaqing Wang, Xiaojie He, Xiaodong Li · 2025 · Frontiers in Endocrinology
96. SGLT2 inhibitor requires co-administration with diuretics to effectively reduce interstitial fluid retention: the DAPA-BODY trial
    Takahiro Masuda, Maki Asakura, Kentaro Oka, Ken Ohara, Masato Sakai, Marina Miura, Kyohei Misawa, Keiji Hirai, Masato Morinari, Tetsu Akimoto et al. · 2025 · Hypertension Research
97. Sodium-glucose transporter 2 inhibitor for obstructive sleep apnea in patients with type 2 diabetes mellitus: A systematic review and meta-analysis
    Rui‐Feng Yang, Qing Zhao, Jiangfan Guo, Lili Wu, Lingling Qin, Tonghua Liu · 2025 · Sleep Medicine
98. Sodium glucose transporter 2 inhibitors: Will these drugs benefit non‐diabetic veterinary patients with cardiac and kidney diseases?
    Jonathan Elliott, Mark A. Oyama · 2024 · Journal of Veterinary Pharmacology and Therapeutics
99. Effects of SGLT2 inhibitors on parameters of renal venous congestion in intrarenal Doppler ultrasonography
    Manuel Wallbach, Jamil Ajrab, Bilgin Bayram, Dennis Pieper, Ann-Kathrin C. Schäfer, Stephan Lüders, Fani Delistefani, D Müller, Michael Johann Koziolek · 2024 · Clinical Kidney Journal
100. Are SGLT2 inhibitors joining the mainstream therapy for diabetes type 2?
     Mortaza Fatehi Hassanabad, Zahra F.H. Abad · 2019 · Diabetes & Metabolic Syndrome Clinical Research & Reviews